NSE · Healthcare · Biotechnology
EPS came in at 2.56 against a street estimate of 5.30 — a miss of 51.7%.
with an average price target of ₹2,056.00.
| Document | Date |
|---|---|
| Investor presentation · Q1 FY27 SUMMARY: ONESOURCE SPECIALTY PHARMA LIMITED HEADLINE NUMBERS • Document is a regulatory filing dated September 3, 2026 • Company: OneSource Specialty | 2026-09-03 |
| Annual report FY2026 ONEOURCE SPECIALTY PHARMA LIMITED – FY2025-26 SUMMARY HEADLINE NUMBERS • Revenue: ₹14,216 million • EBITDA: ₹3,042 million (21% margin) • Adjusted P | 2026-08-31 |
| Quarterly results · Q1 FY27 ONESOURCE SPECIALTY PHARMA LIMITED – Q1 FY2027 INTERIM FINANCIAL REVIEW HEADLINE NUMBERS • Review Period: Quarter ended June 30, 2026 • Review Date: | 2026-07-24 |
| Q4 FY26 earnings call ONESOURCE SPECIALTY PHARMA LIMITED – Q4 FY'26 SUMMARY HEADLINE NUMBERS • Q4 FY'26 Revenue: INR 4,282 million (US$48 million), up 47% sequentially • | 2026-05-19 |
| Quarterly results · Q4 FY26 ONESOURCE SPECIALTY PHARMA LIMITED — AUDITOR'S REPORT SUMMARY HEADLINE NUMBERS • Reporting Period: Year ended March 31, 2026 (audited) and Quarter e | 2026-05-19 |
| Investor presentation · Q4 FY26 ONEOURCE SPECIALTY PHARMA LIMITED — FY26 RESULTS SUMMARY HEADLINE NUMBERS • Q4FY26 Revenue: ₹4,282 million ($47.6m), up 47% quarter-on-quarter; full | 2026-05-13 |
| Q3 FY26 earnings call ONESOURCE SPECIALTY PHARMA LIMITED – Q3 FY'26 SUMMARY HEADLINE NUMBERS • Q3 FY'26 Revenue: INR 2,903 million (US$10 million decline vs Q2; 26% YoY d | 2026-01-30 |
| Quarterly results · Q3 FY26 ONESOURCE SPECIALTY PHARMA LIMITED – Q3 FY2025-26 FINANCIAL SUMMARY HEADLINE NUMBERS • Q3 FY2025-26 Revenue (Standalone): Rs. 2,902.20 million vs Rs | 2026-01-23 |
Readable in the app.
| Announcement | Date |
|---|---|
| In-principle approval received for Unit II expansion project under KIP 2025-30 Onesource Specialty Pharma Limited has received in-principle approval from the Karnataka Government for incentives and concessions related to its Unit II expansion project under the Karnatak | 2026-05-16 |
| FY26 results announced; FY28 guidance reaffirmed with strong Q4 OneSource Specialty Pharma Limited announced its full-year FY26 (ending March 2026) financial results, highlighting strong performance in Q4 FY26. The company reaffirmed its guidance for FY2 | 2026-05-13 |
| Composite scheme of arrangement and amalgamation among multiple entities approved Onesource Specialty Pharma Limited announced a composite merger scheme involving multiple entities: Steriscience Specialties Private Limited, Brooks Steriscience Limited, Steriscience Pte. L | 2026-05-13 |
| Composite scheme of amalgamation merger approved amongst multiple entities Onesource Specialty Pharma Limited has announced a composite merger scheme involving five entities: SteriscienceSpecialties Private Limited, Brooks Steriscience Limited, Steriscience Pte. Li | 2026-03-06 |
| Received NSE/BSE approval for composite scheme of arrangement and amalgamation Strides Pharma and its group companies have received regulatory approval from India's National Stock Exchange (NSE) and BSE to proceed with a major merger and amalgamation. The scheme involv | 2026-02-26 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for ONESOURCE SPECIALTY PHARMA LTD — free to start.
Google PlayApp StoreData updated 2026-09-18.